2 Information about tocilizumab

2 Information about tocilizumab

Marketing authorisation indication

Tocilizumab (RoActemra, Roche) has a marketing authorisation for 'the treatment of adults with giant cell arteritis'.

Dosage in the marketing authorisation

162 mg subcutaneous injection once every week in combination with a tapering course of glucocorticoids. Tocilizumab can be used alone following discontinuation of glucocorticoids, but monotherapy should not be used for the treatment of acute relapses. Treatment beyond 52 weeks should be guided by disease activity, physician discretion and patient choice.


£913.12 for 4 syringes containing 162 mg tocilizumab (excluding VAT).

The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of tocilizumab, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme would not constitute an excessive administrative burden on the NHS.

  • National Institute for Health and Care Excellence (NICE)